TANANBAUM JAMES B. purchased 1.78M shares of KINNATE BIOPHARMA INC. on the open market
Open‑market purchase worth $4.98M. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 5/10/2023ACC: 0001209191-23-028537
Director10% Owner
Since Dec 2020
+1.78M
Net shares
Net buyer
$4.98M
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
1.78M acquired
Non-Derivative Transactions2
Common Stock
Indirect
Shares
+1.55M
Price / share
$2.80
Trade value
$4.34M
% of position
78.5%
5/8/2023
1.98M→3.53M
Common Stock
Indirect
Shares
+229.04K
Price / share
$2.80
Trade value
$641.32K
% of position
78.5%
5/8/2023
291.67K→520.71K
Total
Net shares
+1.78M
Net value
$4.98M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 5/8/2023 | P · Purchase | +1.55M | $2.80 | $4.34M | 78.5% | 1.98M | 3.53M |
| Common Stock Indirect | 5/8/2023 | P · Purchase | +229.04K | $2.80 | $641.32K | 78.5% | 291.67K | 520.71K |
| Total | +1.78M | $4.98M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned9.67M
Total
9.67M indirect9.67M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 9.67M | Indirect |
| Total | 9.67M | 9.67M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported